Steven Vernino

Steven Vernino

Auto-generated profile, based on publicly available information

Steven Vernino

Department of Neurology, University of Texas Southwestern Medical Center, Dallas, USA

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2000 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
SVSteven Vernino
Steven Vernino
PLPhillip A. Low
Phillip A. Low
RFRobert D. Fealey
Robert D. Fealey
JSJohn D. Stewart
John D. Stewart
GFGianrico Farrugia
Gianrico Farrugia
VLVanda A. Lennon
Vanda A. Lennon
Idiopathic autonomic neuropathy is a severe, subacute disorder with a presumed autoimmune basis. It is indistinguishable from the subacute autonomic neuropathy that may accompany lung cancer or other tumors. Autoantibodies specific for nicotinic acetylcholine receptors in the autonomic ganglia are potentially pathogenic and may serve as serologic markers of various forms of autoimmune autonomic neuropathy. We tested serum from 157 patients with a variety of types of dysautonomia. Immunoprecipitation assays with iodine-125–labeled epibatidine and solubilized human neuroblastoma acetylcholine receptors were used to detect autoantibodies that bound to or blocked ganglionic receptors. Ganglionic-receptor–binding antibodies were found in 19 of 46 patients with idiopathic or paraneoplastic autonomic neuropathy (41 percent), in 6 of 67 patients with postural tachycardia syndrome, idiopathic gastrointestinal dysmotility, or diabetic autonomic neuropathy (9 percent), and in none of 44 patients with other autonomic disorders. High levels of the binding antibodies correlated with more severe autonomic dysfunction (including the presence of tonic pupils). Levels of these antibodies decreased in patients who had clinical improvement. All seven patients with ganglionic-receptor–blocking antibodies had ganglionic-receptor–binding antibodies and had idiopathic or paraneoplastic autonomic neuropathy. Seropositivity for antibodies that bind to or block ganglionic acetylcholine receptors identifies patients with various forms of autoimmune autonomic neuropathy and distinguishes these disorders from other types of dysautonomia. The positive correlation between high levels of ganglionic-receptor antibodies and the severity of autonomic dysfunction suggests that the antibodies have a pathogenic role in these types of neuropathy.

1 February 2006 in Archives of Neurology
Verified
Journal Article
Open access
PDF file
PCPablo Castillo
Pablo Castillo
BWBryan Woodruff
Bryan Woodruff
RCRichard Caselli
Richard Caselli
SVSteven Vernino
Steven Vernino
CLClaudia Lucchinetti
Claudia Lucchinetti
BBBrad Boeve
Brad Boeve
Neurologists are often consulted to evaluate patients with acute or subacute encephalopathy. The differential diagnosis for encephalopathy is wide, but the clinical features and findings on blood, cerebrospinal fluid (CSF), electroencephalography (EEG), and neuroimaging studies often (but not always) lead to an accurate diagnosis. Once infectious causes are excluded, an autoimmune or inflammatory process may be suspected on the basis of inflammatory and autoimmune markers in the serum and CSF and meningeal and parenchymal abnormalities on magnetic resonance imaging (MRI) of the brain.

3 January 2017 in Journal of Neurology
Verified
Journal Article
Open access
PDF file
CGChristopher H. Gibbons
Christopher H. Gibbons
PSPeter Schmidt
Peter Schmidt
IBItalo Biaggioni
Italo Biaggioni
CFCamille Frazier-Mills
Camille Frazier-Mills
RFRoy Freeman
Roy Freeman
HKHoracio Kaufmann
Horacio Kaufmann
Neurogenic orthostatic hypotension (nOH) is common in patients with neurodegenerative disorders such as Parkinson’s disease, multiple system atrophy, pure autonomic failure, dementia with Lewy bodies, and peripheral neuropathies including amyloid or diabetic neuropathy. Due to the frequency of nOH in the aging population, clinicians need to be well informed about its diagnosis and management. To date, studies of nOH have used different outcome measures and various methods of diagnosis, thereby preventing the generation of evidence-based guidelines to direct clinicians towards ‘best practices’ when treating patients with nOH and associated supine hypertension. To address these issues, the American Autonomic Society and the National Parkinson Foundation initiated a project to develop a statement of recommendations beginning with a consensus panel meeting in Boston on November 7, 2015, with continued communications and contributions to the recommendations through October of 2016. This paper summarizes the panel members’ discussions held during the initial meeting along with continued deliberations among the panel members and provides essential recommendations based upon best available evidence as well as expert opinion for the (1) screening, (2) diagnosis, (3) treatment of nOH, and (4) diagnosis and treatment of associated supine hypertension.

1 January 1992 in Neuron
Verified
Journal Article
Closed access
SVSteven Vernino
Steven Vernino
MAMariano Amador
Mariano Amador
CLCharles W. Luetje
Charles W. Luetje
JPJim Patrick
Jim Patrick
JDJohn A. Dani
John A. Dani

13 April 2004 in Neurology
Verified
Journal Article
Closed access
PDF file
MTM. J. Thieben
M. J. Thieben
VLV. A. Lennon
V. A. Lennon
BBB. F. Boeve
B. F. Boeve
AAA. J. Aksamit
A. J. Aksamit
MKM. Keegan
M. Keegan
SVS. Vernino
S. Vernino
Objectives: To describe the clinical features and coexisting serum autoantibodies in seven patients with encephalitis associated with autoantibodies to α-dendrotoxin-sensitive voltage-gated potassium channels (VGKCs), and to compare this disorder with other autoimmune encephalopathies. Methods: Clinical information was obtained from a retrospective review of medical records and telephone interviews. All autoantibody testing was performed in a single laboratory. Results: The seven patients were examined for subacute cognitive and behavioral changes. Seizures, usually temporal-onset complex partial type, were documented in six patients, and all seven patients had EEG abnormalities. None had symptoms or signs of neuromuscular hyperexcitability. One described hypersalivation. Four patients had additional autoantibody markers of neurologic autoimmunity (muscle acetylcholine receptor, striational, P/Q-type calcium channel, or GAD65), and two had thyroperoxidase antibodies. Two patients had a history of cancer: one had active prostate adenocarcinoma, and the second had a remote history of tongue carcinoma. Cranial MRI demonstrated mesial temporal lobe abnormalities in all patients. One patient improved spontaneously, and six were treated with IV methylprednisolone. Three improved remarkably with treatment. At follow-up evaluation, one had no cognitive deficits, four had mild persistent short-term memory dysfunction, and two had persistent disabling behavioral deficits. Conclusions: Voltage-gated potassium channel antibodies are a valuable serologic marker of a potentially reversible autoimmune encephalopathy. The neurologic manifestations of this disorder are indistinguishable from paraneoplastic limbic encephalitis but are distinct from Morvan syndrome and Hashimoto encephalopathy.

1 March 2007 in Mayo Clinic Proceedings
Verified
Journal Article
Closed access
MTMark J. Thieben
Mark J. Thieben
PSPaola Sandroni
Paola Sandroni
DSDavid M. Sletten
David M. Sletten
LBLisa M. Benrud-Larson
Lisa M. Benrud-Larson
RFRobert D. Fealey
Robert D. Fealey
WSWin-Kuang Shen
Win-Kuang Shen